As patents for breakthrough acid-suppressing molecules begin to approach their expiration dates across various international territories, generic active ingredient manufacturers are preparing comprehensive bioequivalence pipelines. However, international regulatory authorities like the European Medicines Agency have significantly raised the compliance bar, demanding exhaustive characterization...